Da dasatinib og dets metabolitter har en nyreclearance < 4%, forventes total - clearance ikke at falde hos patienter med nyreinsufficiens.
Since the renal clearance of dasatinib and its metabolites is < 4%, a decrease in total body clearance is not expected in patients with renal insufficiency.